The independent medical news service
04-02-2021 | Oncology | News | Article
Novel immune agent shows early promise in SCLC
AMG 757, a half-life extended, bispecific T-cell engager immunotherapy directed against DLL3, has demonstrated tolerability and antitumor activity in patients with previously treated small-cell lung cancer in a phase 1 trial.